F10
Coagulation factor X
As of the edition of 20 October 2026, F10 (coagulation factor X, UniProt P00742) has 17 drugs tested at it and 18 companies on the list, 3 on route A and 10 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P00742
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 192
- Disease areas
- Heart and blood vessels; Nervous system; Lungs and airways; Blood and lymph; Cancer; Inherited and neonatal; Urinary and reproductive; Pregnancy and women's health
- Registered trials of its drugs
- 761
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 9 |
| Went quiet | 5 |
| Stopped | 3 |
| Total | 17 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Rivaroxaban | Marketed | Phase 4 | none listed |
| Apixaban | Marketed | Phase 4 | Ends 2028 |
| Edoxaban | Marketed | Phase 4 | Ends 2027 |
| Emicizumab | Marketed | Phase 4 | Ends 2029 |
| Darexaban | Went quiet | Phase 3 | none listed |
| Antithrombin iii human | Marketed | Phase 4 | Ended 2003 |
| Bemiparin | Marketed | Phase 3 | none listed |
| Betrixaban | Marketed | Phase 3 | Ends 2026 |
| Antithrombin alfa | Marketed | Phase 4 | Ended 2021 |
| Otamixaban | Went quiet | Phase 3 | none listed |
| Idraparinux | Went quiet | Phase 3 | none listed |
| Idrabiotaparinux sodium | Stopped | Phase 3 | none listed |
12 of 17 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 10 |
| Engaged | 2 |
| Undetermined | 3 |
| Total on the list | 18 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| Daiichi Sankyo | Route B |
| Sanofi | Route A |
The other 15 companies at F10
In the product18 companies in all; 15 are not named here, and no score is.
See the 18 companies at F10, ranked, with the facts behind eachRequest access. Nothing is shown until you do.